Cas:64119-88-6 octahydro-2,6-dimethyl-3,8:4,7-dimethano-2,6-naphthyridine-4,8-dimethanol manufacturer & supplier

Chemical Name:octahydro-2,6-dimethyl-3,8:4,7-dimethano-2,6-naphthyridine-4,8-dimethanol

CAS.NO:64119-88-6

Synonyms:octahydro-2,6-dimethyl-3,8:4,7-dimethano-2,6-naphthyridine-4,8-dimethanol

Molecular Formula:C₁₄H₂₄N₂O₂

Molecular Weight:252.35300

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:46.94000

Exact Mass:252.18400

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like octahydro-2,6-dimethyl-3,8:4,7-dimethano-2,6-naphthyridine-4,8-dimethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,octahydro-2,6-dimethyl-3,8:4,7-dimethano-2,6-naphthyridine-4,8-dimethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,octahydro-2,6-dimethyl-3,8:4,7-dimethano-2,6-naphthyridine-4,8-dimethanol Use and application,octahydro-2,6-dimethyl-3,8:4,7-dimethano-2,6-naphthyridine-4,8-dimethanol technical grade,usp/ep/jp grade.

Related News: In the US, avalglucosidase alfa saw its PDUFA date pushed back by three months, from May 18 to Aug. 18, according to a Sanofi investor presentation in April. 7t-amino-3-methyl-7c-methylsulfanyl-8-oxo-(6rH)-4-oxa-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzyl ester manufacturers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. Nucleotidyltransferase, deoxyribonucleate, III (Escherichia coli strainDEC10a gene polB fragment) suppliers The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus. 7-chloro-2-oxo-5-phenyl-2,3-dihydro-benzo[e][1,4]diazepine-1-carboxylic acid ethylamide vendor & factory In the US, avalglucosidase alfa saw its PDUFA date pushed back by three months, from May 18 to Aug. 18, according to a Sanofi investor presentation in April.,The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo.